Nordic Capital's Acino acquires Takeda's primary care portfolio

Avista Capital Partners and Nordic Capital acquired Acino in 2013 for an enterprise value of CHF 544m. Originally a Nordic Capital Fund VII portfolio company, the firm transferred the company to a continuation vehicle, Nordic Capital CV1. The transfer of nine Nordic Capital portfolio companies in 2018 was worth €2.5bn, according to Unquote. The deal saw Goldman Sachs and Coller Capital invest in the continuation vehicle.

The portfolio will allow Acino to expand its offering in several therapeutic and geographical markets. In addition to the acquisition, which includes some Takeda employees and the rights to around 30 products, the Japan-based pharmaceuticals company has also entered into a multi-year manufacturing and supply agreement, under which Takeda will manufacture products on behalf of Acino.

Takeda acquired rival Shire in a £46bn deal in 2018 and is currently divesting a number of assets to absorb related costs. In July 2019, Takeda was looking to divest a portfolio of pharmaceuticals in western Europe, according to reports.

Company
The acquired portfolio includes approximately 30 products in countries in the Middle East, Africa and Ukraine. The products include pain management, gastroenterology, cardiovascular and respiratory products from Takeda's prescription pharmaceutical and over-the-counter portfolio. An undisclosed number of sales and marketing staff will transition to Acino following the closing. Takeda was founded in 1915.

People
Acino – Steffen Saltofte (CEO).

Advisers
Acquirer – Rothschild & Co (corporate finance); Latham & Watkins (legal); PwC (financial due diligence); McKinsey & Company (commercial due diligence).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• DACH
• Healthcare
• Expansion
• healthcare
• Build-up
• Buy-and-build
• Switzerland
• Nordic Capital
• Acquisition finance